Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
NCT05493267Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid and aldesleukin in Tuberculosis (TB), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Sputum smear and culture negative conversion at 24 months. Started Aug 2022; status: recruiting.
02
Drugs
zoledronic acidaldesleukin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05493267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493267.